Andrew Saik serves as the Chief Financial Officer and Treasurer at ARVINAS INC, a position he has held since joining the company in 2018. With a robust background in finance and biotechnology, Andrew has been instrumental in steering ARVINAS INC towards financial stability and growth. Prior to his role at ARVINAS, Andrew held significant positions at other notable biotech firms, including Alexion Pharmaceuticals, where he served as Vice President of Finance and Corporate Controller. His experience in these roles equipped him with the expertise needed to manage the complex financial landscape of the biotechnology industry. At ARVINAS INC, Andrew's primary responsibilities include overseeing the company's financial strategy, managing investor relations, and ensuring the company's fiscal health. Under his leadership, ARVINAS has successfully navigated several funding rounds and strategic partnerships, which have been crucial for advancing the company's innovative protein degradation technology. Andrew's strategic foresight and financial acumen have been pivotal in positioning ARVINAS as a leader in the development of novel therapeutics. His contributions have not only bolstered the company's financial standing but also supported its mission to bring groundbreaking treatments to patients in need. Andrew holds a Bachelor of Science in Accounting from Villanova University and is a Certified Public Accountant. His professional achievements are further highlighted by his involvement in various industry conferences and panels, where he shares insights on financial strategies within the biotech sector. Andrew's dedication to ARVINAS INC and his role in its success underscore his commitment to advancing the field of biotechnology through sound financial management and strategic planning.